OBJECTIVE: Non-Hodgkin's lymphomas (NHL) are etiologically heterogeneous malignancies. In Egypt, we previously reported an association of increased NHL risk with chronic hepatitis C virus (HCV) infection. Our present aim is to assess the association between HCV infection and histological subtypes of NHL. METHODS: We conducted a case-control study at the National Cancer Institute of Cairo University. Cases with NHL (n = 486) were matched to controls (n = 786) who were orthopedic patients from the same referral regions. Participants provided a blood sample for HCV markers (anti-HCV, HCV RNA) and answered a questionnaire on possible risk factors. Case-control differences were assessed by odds ratios and 95% confidence intervals from logistic regression analysis. RESULTS: Cases with diffuse large B cell lymphoma (n = 146), chronic lymphocytic leukemia (n = 58), marginal zone lymphoma (n = 24), follicular lymphoma (n = 23), and mantle cell lymphoma (n = 16) were recruited. HCV RNA prevalence was 27% in controls and 26%-48% in the NHL subgroups: it was associated (p < 0.001) with diffuse large B cell, marginal zone, and follicular lymphomas with odds ratios of 3.2, 4.4, and 3.3, respectively. CONCLUSION: HCV is a risk factor for diffuse large B cell, marginal zone, and follicular lymphomas in Egypt.
OBJECTIVE:Non-Hodgkin's lymphomas (NHL) are etiologically heterogeneous malignancies. In Egypt, we previously reported an association of increased NHL risk with chronic hepatitis C virus (HCV) infection. Our present aim is to assess the association between HCV infection and histological subtypes of NHL. METHODS: We conducted a case-control study at the National Cancer Institute of Cairo University. Cases with NHL (n = 486) were matched to controls (n = 786) who were orthopedic patients from the same referral regions. Participants provided a blood sample for HCV markers (anti-HCV, HCV RNA) and answered a questionnaire on possible risk factors. Case-control differences were assessed by odds ratios and 95% confidence intervals from logistic regression analysis. RESULTS: Cases with diffuse large B cell lymphoma (n = 146), chronic lymphocytic leukemia (n = 58), marginal zone lymphoma (n = 24), follicular lymphoma (n = 23), and mantle cell lymphoma (n = 16) were recruited. HCV RNA prevalence was 27% in controls and 26%-48% in the NHL subgroups: it was associated (p < 0.001) with diffuse large B cell, marginal zone, and follicular lymphomas with odds ratios of 3.2, 4.4, and 3.3, respectively. CONCLUSION:HCV is a risk factor for diffuse large B cell, marginal zone, and follicular lymphomas in Egypt.
Authors: A Cucuianu; M Patiu; M Duma; C Basarab; O Soritau; A Bojan; A Vasilache; M Mates; L Petrov Journal: Br J Haematol Date: 1999-11 Impact factor: 6.998
Authors: P Hausfater; P Cacoub; E Rosenthal; N Bernard; V Loustaud-Ratti; Z Le Lostec; H Laurichesse; F Turpin; D Ouzan; D Grasset; C Perrone; M P Cabrol; J C Piette Journal: Am J Hematol Date: 2000-06 Impact factor: 10.047
Authors: V De Re; S De Vita; A Marzotto; M Rupolo; A Gloghini; B Pivetta; D Gasparotto; A Carbone; M Boiocchi Journal: Blood Date: 2000-11-15 Impact factor: 22.113
Authors: F Abdel-Aziz; M Habib; M K Mohamed; M Abdel-Hamid; F Gamil; S Madkour; N N Mikhail; D Thomas; A D Fix; G T Strickland; W Anwar; I Sallam Journal: Hepatology Date: 2000-07 Impact factor: 17.425
Authors: Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters Journal: Clin Gastroenterol Hepatol Date: 2008-04 Impact factor: 11.382
Authors: J R Cerhan; R B Wallace; F Dick; J Kemp; A S Parker; W Zheng; T A Sellers; A R Folsom Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-04 Impact factor: 4.254
Authors: Hala A Abdel Rahman; Mervat M Khorshied; Haidy H Elazzamy; Ola M Khorshid Journal: J Cancer Res Clin Oncol Date: 2012-04-07 Impact factor: 4.553
Authors: Anamarija M Perry; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger Journal: Haematologica Date: 2016-06-27 Impact factor: 9.941
Authors: C M Herzog; S Dey; A Hablas; H M Khaled; I A Seifeldin; M Ramadan; H El-Hamzawy; M L Wilson; A S Soliman Journal: Ann Oncol Date: 2012-05-02 Impact factor: 32.976
Authors: C Estes; M Abdel-Kareem; W Abdel-Razek; E Abdel-Sameea; M Abuzeid; A Gomaa; W Osman; H Razavi; H Zaghla; I Waked Journal: Aliment Pharmacol Ther Date: 2015-07-22 Impact factor: 8.171